1. Home
  2. UDMY vs DBVT Comparison

UDMY vs DBVT Comparison

Compare UDMY & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Udemy Inc.

UDMY

Udemy Inc.

HOLD

Current Price

$4.97

Market Cap

1.0B

Sector

Real Estate

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$21.00

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UDMY
DBVT
Founded
2009
2002
Country
United States
France
Employees
N/A
90
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
UDMY
DBVT
Price
$4.97
$21.00
Analyst Decision
Buy
Buy
Analyst Count
10
7
Target Price
$9.00
$31.75
AVG Volume (30 Days)
2.2M
253.8K
Earning Date
05-04-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
105.36
N/A
EPS
0.03
N/A
Revenue
$789,844,000.00
$4,151,000.00
Revenue This Year
$4.44
$1,768.71
Revenue Next Year
$6.02
$1,028.88
P/E Ratio
$175.00
N/A
Revenue Growth
0.42
N/A
52 Week Low
$4.35
$3.82
52 Week High
$9.74
$26.19

Technical Indicators

Market Signals
Indicator
UDMY
DBVT
Relative Strength Index (RSI) 52.34 48.32
Support Level $5.02 $20.11
Resistance Level $5.06 $25.52
Average True Range (ATR) 0.26 1.32
MACD 0.07 -0.17
Stochastic Oscillator 66.83 22.49

Price Performance

Historical Comparison
UDMY
DBVT

About UDMY Udemy Inc.

Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: